| Identification | More | [Name]
N-BOC-piperidine-4-carboxylic acid | [CAS]
84358-13-4 | [Synonyms]
1-(1,1-DIMETHYLETHYL)1,4-PIPERIDINEDICARBOXYLIC ACID
1-BOC-4-PIPERIDINECARBOXYLIC ACID
1-BOC-PIPERIDINE-4-CARBOXYLIC ACID
1-N-BOC-PIPERIDINE-4-CARBOXYLIC ACID
1-(TERT-BUTOXYCARBONYL)PIPERIDINE-4-CARBOXYLIC ACID
AURORA KA-3052
BOC-INP
BOC-INP-OH
BOC-ISONICOT(HEXAHYDRO)-OH
BOC-ISONIPECOTIC ACID
BOC-L-ISONIPECOTIC ACID
BOC-PIC(4)-OH
BOC-PIPERIDINE-4-CARBOXYLIC ACID
BUTTPARK 99\04-45
ISONIPECOTIC ACID, BOC PROTECTED
N-BOC-DL-ISONIPECOTIC ACID
N-BOC-ISONIPECOTIC ACID
N-BOC-PIPERIDINE-4-CARBOXYLIC ACID
N-T-BUTOXYCARBONYL-HEXAHYDROISONICOTINIC ACID
N-T-BUTOXYCARBONYL-PIPERIDINE-4-CARBOXYLIC ACID | [EINECS(EC#)]
700-076-1 | [Molecular Formula]
C11H19NO4 | [MDL Number]
MFCD00076999 | [Molecular Weight]
229.27 | [MOL File]
84358-13-4.mol |
| Chemical Properties | Back Directory | [Appearance]
White crystalline powder | [Melting point ]
148-153 °C
| [Boiling point ]
353.2±35.0 °C(Predicted) | [density ]
1.164±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [form ]
Crystalline Powder | [pka]
4.56±0.20(Predicted) | [color ]
White | [Water Solubility ]
Insoluble in water. | [Detection Methods]
HPLC | [BRN ]
5533442 | [InChI]
InChI=1S/C11H19NO4/c1-11(2,3)16-10(15)12-6-4-8(5-7-12)9(13)14/h8H,4-7H2,1-3H3,(H,13,14) | [InChIKey]
JWOHBPPVVDQMKB-UHFFFAOYSA-N | [SMILES]
N1(C(OC(C)(C)C)=O)CCC(C(O)=O)CC1 | [CAS DataBase Reference]
84358-13-4(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S37/39:Wear suitable gloves and eye/face protection . | [WGK Germany ]
3
| [Hazard Note ]
Irritant | [HazardClass ]
IRRITANT | [HS Code ]
29333990 |
| Hazard Information | Back Directory | [Chemical Properties]
White crystalline powder | [Uses]
It is a pharmaceutical intermediate. he camptothecin ester of isonipecotic acid is installed on a triazine dendrimer intermediate obtained through an iterative, scalable route to ultimately yield cationic and PEGylated targets with activities in cell culture comparable to free drug. | [reaction suitability]
reaction type: Boc solid-phase peptide synthesis | [Synthesis]
General procedure for the synthesis of 1-Boc-4-piperidinecarboxylic acid from methyl 1-Boc-4-piperidinecarboxylate: 4-tert-butyl-4-methylpiperidine-1,4-dicarboxylate (4.84 g, 20 mmol) and LiOH (2.52 g, 60 mmol) were reacted with 4-tert-butyl-4-methylpiperidine-1,4-dicarboxylate (4.84 g, 20 mmol) and LiOH (2.52 g, 60 mmol) in a mixture of THF (90 mL), MeOH (90 mL) and H2O (30 mL) in a solvent, and the reaction was stirred at room temperature overnight. After completion of the reaction, the solvent was removed by distillation under reduced pressure. The residue was adjusted to pH 2 with aqueous 2N HCl. Subsequently, the reaction mixture was extracted with EtOAc (3 × 20 mL). The organic phases were combined, dried over anhydrous Na2SO4 and concentrated under reduced pressure to give 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (4.6 g, 100.0% yield). | [References]
[1] Patent: WO2012/34526, 2012, A1. Location in patent: Page/Page column 56
[2] Patent: US2013/190307, 2013, A1. Location in patent: Paragraph 0205; 0206
[3] Patent: US2016/102095, 2016, A1. Location in patent: Paragraph 0131
[4] Patent: CN104292233, 2016, B. Location in patent: Paragraph 0047
[5] Patent: WO2016/34134, 2016, A1. Location in patent: Paragraph 00538 |
|
|